Market Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Quillivant XR® Patent Challenge

[PR Newswire] – DUBLIN, Oct. 16, 2014 /PRNewswire/ — Actavis plc (ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking . . . → Read More: Market Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Quillivant XR® Patent Challenge Similar Articles: Market Update (NYSE:ACT): Actavis to Acquire Durata Therapeutics, Inc. Stock Update: Actavis plc (NYSE:ACT) – Actavis Confirms Generic Butrans® Patent Challenge Company Update (NYSE:ACT): Actavis to Present at Morgan Stanley Global Healthcare Conference 2014